Gilead Sciences, Inc

Add to watchlist
$68.09
Last updated:06/15/2021
GILD: NASDAQ
Gilead Sciences, Inc

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Evip… Show more

Dividend yield
4.08%
$2.78 anually

3y growth is 9.22%– Yield is 82% higher than average in Health Care sector

P/E ratio
283.71x
vs. 9.59x forward

Price is 283.71x times more than EPS $0.24 which eaquals $68.09

Payout ratio
1158.33%
Yearly

1158.33% of earnings is used as dividends.

CASH payout ratio

Last quarter

Become our supporter to unlock all data!
Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
GILD dividends
Payout frequency
Quarterly
Latest ex-date
06/14/2021
3y growth
9.22%
5y growth
10.23%
$0.57
$0.57
03/15/2018
$0.57
$0.57
06/14/2018
$0.57
$0.57
09/13/2018
$0.57
$0.57
12/13/2018
2018
$2.28
$0.63
$0.63
03/14/2019
$0.63
$0.63
06/13/2019
$0.63
$0.63
09/12/2019
$0.63
$0.63
12/12/2019
2019
$2.52
$0.68
$0.68
03/12/2020
$0.68
$0.68
06/11/2020
$0.68
$0.68
09/14/2020
$0.68
$0.68
12/14/2020
2020
$2.72
$0.71
$0.71
03/12/2021
$0.71
$0.71
06/14/2021
2021
So far
$1.42
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
4.628B
5.455B
+17.87%
5.364B
-1.67%
89M
-98.34%
Cashflow
Sum up money going in and out company
11.898B
8.4B
-29.40%
9.144B
+8.86%
8.168B
-10.67%
Total liabilities
All combined debts and obligations
49.782B
42.141B
-15.35%
38.977B
-7.51%
50.186B
+28.76%
Stock exposure in ETFs
ETF
Percentage of ETF
Become a premium member and see all 52 ETFs that include this stock
Company profile
CEO
Mr. Daniel P. O'Day
Market capitalization
Mega (85.40B)
GILD price history
Loading price stock history...